MarketCap
Catalyst Biosciences CBIO
$ 14.24
0.35%
Facebook
X
Telegram
Catalyst Biosciences General and Administrative Expenses | CBIO
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Catalyst Biosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.8 M | 16.1 M | 14.7 M | 17.4 M | 19 M | 16.2 M | 13.4 M | 12.4 M | 9.99 M | 9.26 M | 9.59 M | 10.2 M | 12 M | 13.2 M | 12.2 M | 8.05 M | 8.17 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 20.8 M | 8.05 M | 13.1 M |
Quarterly General and Administrative Expenses Catalyst Biosciences
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5 K | 7.22 M | 4.32 M | 4.83 M | 4.96 M | - | 3.82 M | 3.42 M | 3.4 M | - | 1.16 M | 1.71 M | 1.74 M | - | 4.36 M | 3.84 M | 4.99 M | - | 4.87 M | 4.52 M | 5.41 M | - | 3.83 M | 4.37 M | 3.69 M | - | 3.27 M | 3.27 M | 3.69 M | - | 2.77 M | 3.22 M | 2.91 M | - | 2.39 M | 2.65 M | 2.38 M | - | 2.42 M | 2.27 M | 2.4 M | - | 2.51 M | 1.74 M | 2.32 M | - | 849 K | 2.87 M | 2.76 M | - | 2.83 M | 3.03 M | 3.49 M | - | 2.43 M | 4.59 M | 3.07 M | - | 2.84 M | 3.13 M | 3.18 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.22 M | 5 K | 3.23 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AnaptysBio
ANAB
|
23.4 M | $ 51.7 | 1.83 % | $ 1.5 B |  USA |
 |
Allakos
ALLK
|
38.8 M | - | - | $ 28.6 M | USA |
 |
Bicycle Therapeutics plc
BCYC
|
79.4 M | $ 3.73 | 3.61 % | $ 258 M |  Britain |
 |
Black Diamond Therapeutics
BDTX
|
16.6 M | $ 1.89 | 0.53 % | $ 107 M | USA |
 |
Clovis Oncology
CLVS
|
33.3 M | - | -7.23 % | $ 13 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
22.5 M | - | - | $ 401 M | USA |
 |
Rezolute
RZLT
|
29.2 M | $ 3.94 | 1.87 % | $ 299 M | USA |
 |
Evelo Biosciences
EVLO
|
29.9 M | - | -14.46 % | $ 27.9 M | USA |
 |
BioLineRx Ltd.
BLRX
|
3.14 M | $ 2.52 | 1.17 % | $ 6.21 B |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
1.15 B | $ 61.35 | 0.06 % | $ 11.8 B | USA |
 |
Benitec Biopharma
BNTC
|
27.8 M | $ 9.64 | 0.46 % | $ 449 M | USA |
 |
BioNTech SE
BNTX
|
514 M | $ 99.26 | 0.81 % | $ 24 B |  Germany |
 |
Freeline Therapeutics Holdings plc
FRLN
|
30.7 M | - | - | $ 384 M | Britain |
 |
Genocea Biosciences
GNCA
|
14.7 M | - | -15.0 % | $ 3.04 M | USA |
 |
Burford Capital Limited
BUR
|
38.4 M | $ 3.63 | 3.93 % | $ 795 M | Britain |
|
Amryt Pharma plc
AMYT
|
92 M | - | - | $ 621 M | Britain |
 |
G1 Therapeutics
GTHX
|
71.1 M | - | - | $ 370 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.66 M | $ 2.17 | 0.46 % | $ 3.57 M | Israel |
 |
C4 Therapeutics
CCCC
|
36.2 M | $ 3.03 | 0.3 % | $ 251 M | USA |
 |
Codexis
CDXS
|
47.1 M | $ 1.37 | 1.45 % | $ 119 M | USA |
 |
Cerus Corporation
CERS
|
80.9 M | $ 2.61 | 0.38 % | $ 497 M | USA |
 |
AbbVie
ABBV
|
14 B | $ 265.12 | 0.09 % | $ 469 B | USA |
 |
Humanigen
HGEN
|
15.6 M | - | -81.12 % | $ 4.28 M | USA |
 |
Coherus BioSciences
CHRS
|
101 M | $ 1.17 | 1.48 % | $ 137 M | USA |
 |
AbCellera Biologics
ABCL
|
83.2 M | $ 12.65 | 2.76 % | $ 3.78 B |  Canada |
 |
Abeona Therapeutics
ABEO
|
65 M | $ 5.43 | 2.65 % | $ 288 M | USA |
 |
Celldex Therapeutics
CLDX
|
43.8 M | $ 31.48 | 1.16 % | $ 2.09 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
4.83 M | $ 4.12 | 1.98 % | $ 50.3 M | Israel |
 |
Фармсинтез
LIFE
|
24.1 M | - | - | - |  Russia |
 |
Cellectar Biosciences
CLRB
|
11.5 M | $ 2.08 | 0.48 % | $ 5.43 M | USA |
 |
IGM Biosciences
IGMS
|
50.4 M | - | - | $ 76.9 M | USA |
 |
IMV
IMV
|
17 M | - | - | $ 13.1 M | Canada |
 |
Kinnate Biopharma
KNTE
|
28.2 M | - | - | $ 123 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
15.7 M | - | - | $ 231 M | USA |
 |
Karuna Therapeutics
KRTX
|
131 M | - | - | $ 12.2 B | USA |
 |
Cocrystal Pharma
COCP
|
3.96 M | $ 1.15 | 1.67 % | $ 13 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
191 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Collegium Pharmaceutical
COLL
|
67.6 M | $ 22.64 | 0.85 % | $ 717 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
449 M | $ 118.51 | 4.93 % | $ 12.3 B | USA |
 |
Chimerix
CMRX
|
22.2 M | - | - | $ 756 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
15.2 M | $ 7.45 | 0.19 % | $ 99.2 M | USA |
 |
Curis
CRIS
|
14 M | $ 0.88 | 0.85 % | $ 11.6 M | USA |
 |
CorMedix
CRMD
|
68.2 M | $ 7.77 | 1.04 % | $ 560 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
73.5 M | $ 55.7 | 0.23 % | $ 5.01 B |  Schweiz |
 |
Corvus Pharmaceuticals
CRVS
|
9.25 M | $ 11.8 | 8.21 % | $ 932 M | USA |
|
Champions Oncology
CSBR
|
11.2 M | $ 4.95 | 0.38 % | $ 68.5 M | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
15.9 M | $ 4.88 | 0.62 % | $ 935 M | Canada |
 |
Cue Biopharma
CUE
|
16.2 M | $ 32.85 | 3.6 % | $ 3.11 B | USA |
 |
CEL-SCI Corporation
CVM
|
8.92 M | $ 1.72 | 2.38 % | $ 13.8 M | USA |